Hospital Uiversitario y Politécnico La Fe
Valencia, 46026, Spain
NCT Number: NCT05944094
The aim of this prospective observational study was to evaluate the efficacy of a universal strategy of primary prevention of preterm birth using intravaginal chlorhexidine (CLX) applied before 16 weeks.
The main question is whether universal treatment with vaginal CLX before 16 weeks would reduce the incidence of preterm birth, especially before 34 weeks.
Participants were recruited at the routine first trimester consultation. All patients underwent an initial ultrasound examination between 6+0 and 15+6 weeks gestation, including assessment of embryo/fetus vitality.
Antiseptic treatment aimed at reducing possible bacterial overgrowth consisted of 10 days (1 box) of CLX vaginal ovules (CLX digluconate 0.2%) always starting between 9+0 and 16+0 weeks.
As this product is widely marketed and frequently indicated in gynaecology, we did not deprive the non-treated group of treatment because we wanted to assess whether it could have an effect on reducing preterm delivery.
The pregnant women were then followed up until the end of pregnancy and compared with a cohort of patients who had not received any treatment.
All data related to delivery were collected, as well as any events related to preterm delivery, such as onset of contractions, cervical shortening and premature rupture of membranes, regardless of final gestational age at delivery.
Looking for future studies?
Notify Me18 year–40 year
Female
Observational
Valencia, 46026, Spain
Clinical implications of the study:
The clinical implications of our project would be to counteract the effect of pathogenic bacteria from the beginning of pregnancy (outside the teratogenic period) with the administration of the CLX ovules and thus enhance the action of the normal vaginal microbiota in the pregnant patient, since the glycogen available due to hormonal action favours the growth and development of lactobacillus, responsible for its protective activity against pathogens during pregnancy.
Sample size:
The approximate number of births per year in Spain is 370,000. The minimum number of patients to be recruited would be 400 with a 95% confidence interval.
Patients were recruited as they attended the consultation where the PI and/or collaborators were present.
Variables:
Statistical analysis Continuous variables were presented as mean and standard deviations (SD), median and interquartile range (IQR), while categorical variables were presented as absolute numbers and relative frequencies. Characteristics between both cohorts were compared by mean of Mann- Whitney and Fisher tests. Finally, to assess the validity of results and ensure consistency an additional multivariable analysis was performed adjusting for clinical parameters, to evaluate the odds ratio (OR) of the different determinants in the prediction of preterm birth. Finally, preterm birth incidence was calculated for specific groups selected according to the multivariable analysis result. Statistical analysis and graphs were done using Graph Pad Prism®, Mac version 9.0.1, and Stat Plus® Mac Pro version 8.0.1.s. Permissions were obtained from La Fe hospital review board and from the Valencian Autonomic Government health authorities (reference: PLUVA, date 4-2-2021). Written informed consent was retrieved to participate in the study. The authors report no conflicts of interest.
Quality control:
All analyses were performed on a single sample of patients who met the selection criteria and who had all the information required for the variables to be analysed.
In cases where it was not possible to obtain this information, the following were excluded from the study
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Healthy pregnant patients from the 9 weeks until 15weeks 6 days who attend the first trimester check-up
Exclusion criteria
Patients with a history of previous preterm birth.
Antiseptic treatment aimed at reducing potential bacterial overgrowth consisted of 10 days (1 box) of vaginal ovules of CLX (CumLaude CLX ® , CLX digluconate 0.2%) always starting between 10+0 and 16+0 weeks.
Other names: Code GMDN (Global Medical Device Nomenclature): 47673 - Vaginal mucosa suppository Code NBOG (Notified Body Operations Group): MD0303- CumLaude CLX ®
Time frame: 9 months
Vaginal delivery before 34 weeks
Time frame: 9 months
Cervical shortening below 25 mm before 34 weeks
Time frame: 9 months
presence of regular uterine contractions associated with cervical modifications (dilatation and/or shortening of the cervix) before 37 weeks
Time frame: 9 months
Premature rupture of membranes before 37 weeks
Instituto de Investigacion Sanitaria La Fe
Other
Evaluation of the Efficacy of Chlorhexidine Use During the First Trimester as a Regulator of Vaginal Microbiota in Reducing Preterm Birth
Acronym: PLUVA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07695467
Female Urogenital Diseases and Pregnancy Complications, Obstetric Labor Complications
Sivas, Kayseri Ave, Turkey (Türkiye)
View Trial DetailsNCT05576207
Anemia of Pregnancy, Birth Weight
Rangpur City, Bangladesh
View Trial DetailsNCT03646578
Female Urogenital Diseases and Pregnancy Complications, Obstetric Labor Complications
Amiens, France
View Trial DetailsNCT07305935
Female Urogenital Diseases and Pregnancy Complications, Obstetric Labor Complications
Multan, Punjab Province, Pakistan
View Trial Details